Reimbursement granted to orphan drug in 3 Nordic countries

Wickstrøm & Langkilde ApS supported Norgine by preparing price & reimbursement applications for XIFAXAN/TARGAXAN (rifaximin) in three Nordic countries (Norway, Sweden and Finland). General reimbursement was granted in the three countries 10 months after the project was initiated.

XIFAXAN 550 mg is an antibiotic treatment for adults living with hepatic encephalopathy (HE)—a serious complication of liver disease (cirrhosis). XIFAXAN® (rifaximin) 550 mg tablets are indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18 years of age.

Wickstrøm & Langkilde prepared the reimbursement applications in line with the country specific requirements, adapted a global core model to reflect the country specific requirements and submitted the applications in each of the markets. Questions from authorities were handled efficiently in order not to delay time to market. The project was undertaken in close collaboration with the Nordic office as well as the Global organization in order to ensure a quick and smooth process.

Wickstrøm & Langkilde has a detailed insight knowledge about the Nordics reimbursement processes. The consultants are very flexible and deliver high quality solutions according to our needs and company capabilities. We found the consultants to be very service minded and they often go beyond agreed scope to deliver the best solution

Peter Legarth, General Manager, Nordic. and Anette Koch Jensen, Nordic Business Unit Manager. Norgine